First PI3K Inhibitor for Breast Cancer
Alpelisib has received FDA approval for postmenopausal women, and men, with advanced or metastatic breast cancer whose tumors have a mutation in the PIK3CA gene. The drug is indicated for use in combination with the antiestrogen medication fulvestrant to treat hormone receptor (HR) –positive, human epidermal growth factor receptor 2 (ERBB2)–negative tumors after endocrine-based therapy.
Source: JAMA - Category: General Medicine Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | General Medicine | Genetics | Hormones | Women